

VOLUME 27 1987

SUBJECT INDEX

- Acetylcholine release, 491
amnesia
aniracetam
drug interactions
oxiracetam
scopolamine
Acoustic startle, 749
diethylpropion
fenfluramine
phentermine
phenylpropanolamine
Acquisition, 483
radial maze performance
scopolamine
spatial maze
strain differences
 ACTH_{4-10} , 133
learning performance
long-term effects
neonatal exposure
Adiposity, 223
castration
chickens
sex differences
strain differences
testosterone
 $\beta 1$ Adrenergic receptors, 21
 $\beta 2$ adrenergic receptors
hypothermia
reserpine
 $\beta 2$ Adrenergic receptors, 21
 $\beta 1$ adrenergic receptors
hypothermia
reserpine
Age differences
body weight, 7
data management, 545
locomotor activity, 545
microcomputer, 545
nipple attachment, 7
serotonin, 7
Aggression, 641
attack
attack inhibition
ethanol
Aggression, female, 645
ethanol
opponent size
Alcohol preference, 317
brain monoamines
inbred strains
Ambient temperature, 431
amphetamine
autonomic thermoregulation
behavioral thermoregulation
Ambulation, 359
exploratory behavior
grooming
imipramine chronic
novel environment
social isolation
Amnesia, 491
acetylcholine release
aniracetam
drug interactions
oxiracetam
scopolamine
Amphetamine
ambient temperature, 431
area postrema, 677
ascorbic acid labels, 231
autonomic thermoregulation, 431
behavioral thermoregulation, 431
combined treatment, 677
conditioned taste aversion, 677
continuous reinforcement, 205
environment-specific conditioning, 61
extinction, 205
haloperidol, 231
horizontal activity, 61
intracranial administration, 113
in vivo, 231
nonreinforcement, 205
open field, 113
partial reinforcement, 205
radiation, 677
sensitization, 61
stereotyped behavior, 113
uric acid levels, 231
vertical activity, 61
d-Amphetamine
l-amphetamine, 649
dopaminergic substrate, 649
drug comparisons, 649
drug interactions, 165
food competition, 707
food intake, 649
hypermotility, 165
methylphenidate, 513
metoclopramide, 165
rats, male, 707
route of administration, 165
stereotypy, 165
timing, 513
l-Amphetamine, 649
d-amphetamine
dopaminergic substrate
drug comparisons
food intake
Amytriptyline, 105
body weight
chronic administration
desipramine
food intake
tricyclic antidepressants
Analgesia
catalepsy, 611
dopaminergic system, 457
estrogen, 611
hyperactivity, 611
lesions, electrical, 457
morphine, 457, 611
ovariectomy, 611
U-50,488H, 457
Anatomical mapping, 177
anorexia
calcitonin
hypothalamus
Anhedonia
consummatory behaviors, 341
lever pressing, 67
motor deficit, 341
neuroleptics, 341
operant behaviors, 341
pimozide, 67
rats, nondeprived, 67
sucrose reward, 67
Animal models, 385
drug reinforcement
phencyclidine
phencyclonoids
self-administration, intravenous
Aniracetam, 491
acetylcholine release
amnesia
drug interactions
oxiracetam
scopolamine
Anorectic drugs, 291
2-deoxy-D-glucose
deprivation-induced feeding
glucoprivic-feeding
site of action
Anorexia, 177
anatomical mapping
calcitonin
hypothalamus
Antiaversive effects, 437
antiemetic effects
aversive effects
conditioned taste aversion
drug interaction
opioid receptor agonists
Anticholinergics, 81
cholinergics
conditioned taste aversion
drug interaction
pharmacological antagonism
Antiemetic effects, 437
antiaversive effects
aversive effects
conditioned taste aversion
drug interaction
opioid receptor agonists
Antimuricidal effect, 123
p-chlorophenylalanine
dorsal raphe nucleus
lesions, dorsal raphe nucleus
lesions, electrolytic
lesions, median raphe nucleus
median raphe nucleus
mouse killing behavior
serotonin-mimetic drugs
serotonin neurotransmission
Antipsychotic drugs, 399
body weight
caloric intake
D2 receptors
dose-dependent effects

- long term administration
- male/female comparisons
- Anxiety**, 171
 - buspirone
 - conflict behavior
 - diazepam
 - drug comparisons
 - phenobarbital
 - punished responding
 - unpunished responding
- Anxiolytic agents**, 239
 - exploratory behavior
 - subchronic treatment
 - withdrawal
- Apparatus**
 - Alzet osmotic pump, 199
 - Digiscan Animal Activity Monitor, 545, 553, 565, 573, 583, 569
 - inhalation chamber, 653
 - radial maze, 483, 625
 - Stone maze, 407
 - treadmill, 159
- Area postrema**, 677
 - amphetamines
 - combined treatment
 - conditioned taste aversion
 - radiation
- Ascorbic acid levels**, 231
 - amphetamine
 - haloperidol
 - in vivo*
 - uric acid levels
- Attack**, 641
 - aggression
 - attack inhibition
 - ethanol
- Attack inhibition**, 641
 - aggression
 - attack
 - ethanol
- Audiogenic seizures**, 443
 - hypocalcemia
 - magnesium deficiency
 - potassium levels
- Automated behavior observation**, 559
 - pattern analysis
- Automated monitor**, 565
 - behavioral measures
 - reliabilities
 - spontaneous motor activity
 - time course
- Autonomic thermoregulation**, 431
 - ambient temperature
 - amphetamine
 - behavioral thermoregulation
- Autoshaping**, 307
 - desglycineamide arginine vasopressin learning/memory
 - lever-touch response
 - scopolamine
- Aversive effects**, 437
 - antiaversive effects
 - antiemetic effects
 - conditioned taste aversion
 - drug interaction
 - opioid receptor agonists
- Barbiturates**, 391
 - benzodiazepines
 - drug reinforcement
 - human/monkey/rodent comparisons
- route of administration**
 - self-administration
- Bar-pressing**, 463
 - dopamine agents
 - drinking
 - schedule-induced polydipsia
 - water deprivation
- Behavioral changes**, 407
 - open field activity
 - organophosphate exposure
 - T-maze learning
- Behavioral genetics**
 - caffeine, 451
 - DMCM, 451
 - ethanol stimulation, 577
 - hyporesponsiveness, 451
 - inbred mice, 451
 - open field, 577
 - pharmacogenetics, 577
 - seizures, caffeine-induced, 451
 - selective breeding, 577
- Behavioral measures**, 565
 - automated monitor
 - reliabilities
 - spontaneous motor activity
 - time course
- Behavioral sensitivity**, 99
 - diazepam
 - long-term effects
 - pentylenetetrazole
 - stress
- Behavioral thermoregulation**, 431
 - ambient temperature
 - amphetamine
 - autonomic thermoregulation
- Benzodiazepine receptor agonist**, 35
 - benzodiazepine receptor antagonist
 - gastric ulcers, stress-induced
- Benzodiazepine receptor antagonist**, 35
 - benzodiazepine receptor agonist
 - gastric ulcers, stress-induced
- Benzodiazepine receptors**, 425
 - hypertonic saline intake
 - rehydration
- Benzodiazepines**, 391
 - barbiturates
 - drug reinforcement
 - human/monkey/rodent comparisons
 - route of administration
 - self-administration
- B-HT 920**, 283
 - B-HT 933
 - clonidine
 - differential effects
 - drug comparisons
 - locomotor activity
 - wall-climbing
- B-HT 933**, 283
 - B-HT 920
 - clonidine
 - differential effects
 - drug comparisons
 - locomotor activity
 - wall-climbing
- Bin analysis**, 497
 - 5-HT antagonists
 - 5-HT receptors
 - lesions, 5,7-dihydroxytryptamine
 - locomotor activity
 - motor habituation
- Biogenic amine concentrations**, 257
 - catecholamine depletion
- chicks**
- food intake**
- 6-hydroxydopamine**
- Blood serum cholinesterase**, 199
- osmotic pump**
- premature release**
- pyridostigmine**
- Body weight**
 - age differences, 7
 - amytriptyline, 105
 - antipsychotic drugs, 399
 - caloric intake, 399
 - chronic administration, 105
 - D2 receptors, 399
 - desipramine, 105
 - dose-dependent effects, 399
 - food intake, 105
 - long term administration, 399
 - male/female comparisons, 399
 - nipple attachment, 7
 - serotonin, 7
 - tricyclic antidepressants, 105
- Brain**
 - amygdala, 113, 407
 - anterior hypothalamus, 177
 - anteromedial caudate nucleus, 113
 - aria postrema, 113, 677
 - brainstem, 257, 355, 685
 - caudate, 231
 - caudate-putamen, 457
 - cerebellum, 217, 355, 665
 - cortex, 143, 217, 355, 491, 505, 619, 723
 - dorsal raphe nucleus, 123
 - forebrain, 153
 - frontal cortex, 635
 - hindbrain, 143
 - hippocampus, 143, 217, 355, 407, 491, 505, 619, 635
 - hypothalamus, 143, 177, 183, 257, 291, 355, 619, 685, 715
 - lateral hypothalamus, 521, 693
 - medial frontal cortex, 113
 - medial prefrontal cortex, 15, 693
 - median forebrain bundle, 177
 - median raphe nucleus, 45, 123
 - midbrain, 143, 355
 - nucleus accumbens, 113, 177, 183, 685
 - olfactory tubercle, 177
 - paraventricular nucleus, 177, 291
 - perifornical area, 177
 - piriform cortex, 407
 - posterior nucleus of the hypothalamus, 177
 - prefrontal cortex, 685
 - septum, 685
 - stria medullaris, 183
 - striatum, 53, 143, 183, 257, 355, 491, 533, 583
 - substantia nigra, 457
 - suprachiasmatic nucleus, 177
 - thalamus, 407
 - vasa differentia, 227
 - ventral tegmental area, 457
 - ventrolateral caudate nucleus, 113
 - ventrolateral hypothalamus, 177
 - ventromedial nucleus of the hypothalamus, 177
 - zona incerta, 183
- Brain extract**, 537
 - intraperitoneal injection
 - paradoxical sleep inducing factor

- Brain 5-HT levels, 619
 diazepam
 plasma corticosterone
 stress
 Brain monoamines, 317
 alcohol preference
 inbred strains
 Buspirone, 171
 anxiety
 conflict behavior
 diazepam
 drug comparisons
 phenobarbital
 punished responding
 unpunished responding
- Ca channels, 227
 diabetics
 hyperactivity
 vasa deferentia
 Caffeine, 451
 behavioral genetics
 DMCM
 hyporesponsiveness
 inbred mice
 seizures, caffeine-induced
- Calcitonin
 anatomical mapping, 177
 anorexia, 177
 hypothalamus, 177
 intracerebral infusions, 183
 locomotor activity, drug-induced, 183
- Calcium antagonists, 217
 cat brain
 electroconvulsive shock
 ^{[3]H}nitrendipine binding
- Caloric intake, 399
 antipsychotic drugs
 body weight
 D2 receptors
 dose-dependent effects
 long term administration
 male/female comparisons
- Castration
 adiposity, 223
 chemical delivery system, 265
 chickens, 223
 copulation, 265
 estradiol, 265
 sex differences, 223
 strain differences, 223
 testosterone, 223
- Cat brain, 217
 calcium antagonists
 electroconvulsive shock
 ^{[3]H}nitrendipine binding
- Catalepsy
 analgesia, 611
 conditioned avoidance behavior, 57
 dopamine turnover, 159
 estrogen, 611
 haloperidol, 159
 hyperactivity, 611
 locomotor activity, 159
 morphine, 611
 ovariectomy, 611
 repeated testing, 159
 treadmill, 159
- Catecholamine depletion, 257
 biogenic amine concentrations
 chicks
- food intake
 6-hydroxydopamine
 Catecholamine neurotransmitter, 715
 2-deoxy-D-glucose
 food deprivation
 lateral hypothalamus
 norepinephrine release
 satiety
- Central nervous system, 323
 depressants
 drug interactions
 mice/rat comparisons
 phenacyclidine
- Central nervous system depression, 745
 ethanol
 muscimol
 sleep time
- Cerebellum, mouse, 665
 chloride channels
 ethanol treatments
 in vitro
- Cerebral catecholamine systems, 685
 corticotropin-releasing factor
 stress
- Chemical delivery system, 265
 castration
 copulation
 estradiol
- Chicken
 adiposity, 223
 biogenic amine concentrations, 257
 castration, 223
 catecholamine depletion, 257
 food intake, 25, 257
 6-hydroxydopamine, 257
 opioid antagonists, 25
 sex differences, 223
 strain differences, 223
 testosterone, 223
 water intake, 25
- Chloride channels, 665
 cerebellum, mouse
 ethanol treatments
 in vitro
- p-Chlorophenylalanine, 123
 antimuricidal effect
 dorsal raphe nucleus
 lesions, dorsal raphe nucleus
 lesions, electrolytic
 lesions, median raphe nucleus
 median raphe nucleus
 mouse killing behavior
 serotonin-mimetic drugs
 serotonin neurotransmission
- Choline uptake, 635
 classical conditioning
 microwaves
 tolerance
- Cholinergics, 81
 anticholinergics
 conditioned taste aversion
 drug interaction
 pharmacological antagonism
- Chronic administration, 105
 amitriptyline
 body weight
 desipramine
 food intake
 tricyclic antidepressants
- Chronic consumption, 333
 ethanol
 growth
- lactation
 mammary gland composition
 metabolism
 milk composition
 milk production
- Chronic treatment, 143
 diisopropylfluorophosphate
 muscarinic binding
 spatial learning
- Circadian rhythms, 413
 cortisol
 human studies
 mood ratings
 stress
 urine secretion
- Classical conditioning, 635
 choline uptake
 microwaves
 tolerance
- Clonidine
 B-HT 920, 283
 B-HT 933, 283
 consummatory negative contrast, 659
 differential effects, 283
 drug comparisons, 283
 locomotor activity, 283
 novel environment, 659
 stress, 659
 wall-climbing, 283
- CNS stimulants, 299
 DRL performance
 lethality
 “look-alike” stimulants
 stimulant interaction
- Cocaine, 533
 dopamine release
 sensitization
- Cognitive tasks, 273
 diazepam
 human studies, elderly adults
 neuromotor skills
 pharmacodynamics
- Cold-water swim analgesia, 525
 naloxone, chronic
 morphine analgesia
- Combined treatment
 amphetamines, 677
 area postrema, 677
 conditioned taste aversion, 671, 677
 lithium chloride, 671
 radiation, 671, 677
- Conditioned analgesia, 529
 endogenous opioids
 quaternary naltrexone
 stress-induced analgesia
- Conditioned avoidance behavior, 159
 catalepsy
 dopamine turnover
 haloperidol
 locomotor activity
 repeated testing
 treadmill
- Conditioned taste aversion
 amphetamines, 677
 antiaversive effects, 437
 anticholinergics, 81
 antiemetic effects, 437
 area postrema, 677
 aversive effects, 437
 cholinergics, 81
 combined treatment, 671, 677
 drug interaction, 81, 437

- feed refusal, 247
- food consumption, 247
- lithium chloride, 671, 677
- opioid receptor agonists, 437
- pharmacological antagonism, 81
- radiation, 671, 677
- saccharin, 247
- vomitoxin, 247
- Conflict behavior, 171
 - anxiety
 - buspirone
 - diazepam
 - drug comparisons
 - phenobarbital
 - punished responding
 - unpunished responding
- Consummatory behaviors, 341
 - anhedonia
 - motor deficit
 - neuroleptics
 - operant behaviors
- Consummatory negative contrast, 659
 - clonidine
 - novel environment
 - stress
- Continuous reinforcement, 205
 - amphetamine
 - extinction
 - nonreinforcement
 - partial reinforcement
- Controlling factors, 367
 - drug reinforcement
 - operant behavior
 - self-administration
- Copulation, 265
 - castration
 - chemical delivery system
 - estradiol
- Corticotropin-releasing factor, 685
 - cerebral catecholamine systems
 - stress
- Cortisol, 413
 - circadian rhythms
 - human studies
 - mood ratings
 - stress
 - urine secretion
- D2 receptors, 399
 - antipsychotic drugs
 - body weight
 - caloric intake
 - dose-dependent effects
 - long term administration
 - male/female comparisons
- Data management, 545
 - age differences
 - locomotor activity
 - microcomputer
- Day-night nociception, 477
 - locomotor activity
 - opiate agonists
 - sex differences
- 2-Deoxy-D-glucose
 - anorectic drugs, 291
 - catecholamine neurotransmitter, 715
 - deprivation-induced feeding, 291
 - food deprivation, 715
 - glucoprivic-feeding, 291
 - lateral hypothalamus, 715
 - norepinephrine release, 715
- satiety, 715
 - site of action, 291
- Depolarization-dependent Ca^{2+} uptake, 355
 - ethanol preference
 - neurotransmission
- Depressants, 323
 - central nervous system
 - drug interactions
 - mice/rat comparisons
 - phencyclidine
- Deprivation-induced feeding, 291
 - anorectic drugs
 - 2-deoxy-D-glucose
 - glucoprivic-feeding
 - site of action
- Desmognathamide arginine vasopressin, 307
 - autoshrimping
 - learning/memory
 - lever-touch response
 - scopolamine
- Desipramine, 105
 - amitriptyline
 - body weight
 - chronic administration
 - food intake
 - tricyclic antidepressants
- Diabetics, 227
 - Ca channels
 - hyperactivity
 - vasa deferentia
- Diazepam
 - anxiety, 171
 - behavioral sensitivity, 99
 - brain 5-HT levels, 619
 - buspirone, 171
 - cognitive tasks, 273
 - conflict behavior, 171
 - drug comparisons, 171
 - human studies, elderly adults, 273
 - long-term effects, 99
 - neuromotor skills, 273
 - pentylenetetrazol, 99
 - pharmacodynamics, 273
 - phenobarbital, 171
 - plasma corticosterone, 619
 - punished responding, 171
 - stress, 99, 619
 - unpunished responding, 171
- Dietary fat, 1
 - food intake regulation
 - macronutrient selection
 - monoamine oxidase
 - serotonin metabolism
- Diethylpropion, 749
 - acoustic startle
 - fenfluramine
 - phentermine
 - phenylpropanolamine
- Differential effects, 283
 - B-HT 920
 - B-HT 933
 - clonidine
 - drug comparisons
 - locomotor activity
 - wall-climbing
- Digiscan activity, 569
 - emotionality
 - locomotor activity
 - stereotypic behavior measurement
 - thigmotactic measurement
- Diisopropylfluorophosphate, 143
 - chronic treatment
 - muscarinic binding
 - spatial learning
- DMCM, 451
 - behavioral genetics
 - caffeine
 - hyporesponsiveness
 - inbred mice
 - seizures caffeine-induced
- Dopamine, 93
 - estrogen
 - inhibitory mechanisms
 - lordosis
 - serotonin
- Dopamine agents, 463
 - bar-pressing
 - drinking
 - schedule-induced polydipsia
 - water deprivation
- Dopamine-receptor blockade, 521
 - pimozide
 - stimulation-induced feeding
- Dopamine receptors, 629
 - dopamine behavior
 - hypophsectomy
- Dopamine release, 533
 - cocaine
 - sensitization
- Dopamine turnover, 159
 - catalepsy
 - conditioned avoidance behavior
 - haloperidol
 - locomotor activity
 - repeated testing
 - treadmill
- Dopaminergic behavior, 629
 - dopamine receptors
 - hypophsectomy
- Dopaminergic substrate, 649
 - d-amphetamine
 - l-amphetamine
 - drug comparisons
 - food intake
- Dopaminergic system, 457
 - analgesia
 - lesions, electrical
 - morphine
 - U-50,488H
- Dorsal raphe nucleus, 123
 - antimuricidal effect
 - p-chlorophenylalanine
 - lesions, dorsal raphe nucleus
 - lesions, electrolytic
 - lesions, median raphe nucleus
 - median raphe nucleus
 - mouse killing behavior
 - serotonin-mimetic drugs
 - serotonin neurotransmission
- Dose-dependent effects
 - antipsychotic drugs, 399
 - body weight, 399
 - caloric intake, 399
 - D2 receptors, 399
 - drug comparisons, 733
 - fixed consecutive number responding, 733
 - kappa opioids, 733
 - long term administration, 399
 - male/female comparisons, 399
 - mu opioids, 733
 - sigma opioids, 733

- Dose response, 573
 locomotor activity
 radioprotection
 time relationship
 WR-2721
- Drinking
 bar-pressing, 463
 dopamine agents, 463
 schedule-induced polydipsia, 463
 water deprivation, 463
- DRL performance, 299
 CNS stimulants
 lethality
 "look-alike" stimulants
 stimulant interaction
- Drug
 N-allylnormetazocine, 733
 (\pm) N-allylnormetazocine, 73
 amphetamine, 61, 113, 183, 205, 231, 291, 431, 569
 d-amphetamine, 165, 513, 649, 707, 733
 l-amphetamine, 649
 amytriptyline, 105
 aniracetam, 491
 AP7, 553
 apomorphine, 93, 437, 463
 atropine methyl nitrate, 81
 atropine sulfate, 81
 benactyzine hydrochloride, 81
 betaxolol, 21
 B-HT 920, 283
 B-HT 933, 283
 bremazocine, 73, 437
 buprenorphine, 733
 buspirone, 171, 425
 caffeine, 451
 carbamylcholine, 723
 CGS 8216, 425
 CGS 9895, 425
 CGS 9896, 425
 CGS 19755, 553
 chlordiazepoxide, 35
 p-chlorophenylalanine, 45, 123
 cinanserin, 497
 cis-flupenthixol, 341
 citalopram, 123
 CL 218,872, 425
 clenbuterol, 21
 clonidine, 283, 659
 cocaine, 533
 copper sulphate, 437
 CPP, 553
 d-cyclazocine, 733
 2-deoxy-D-glucose, 105, 291, 715
 desipramine, 105
 desmethylimipramine, 7
 diazepam, 99, 171, 239, 273, 619
 diethylpropion, 749
 diisopropylfluorophosphate, 143
 DMCM, 451
 domperidone, 437
 estradiol, 265
 ethanol, 15, 235, 323, 333, 355, 379, 421, 517, 577, 641, 645, 665, 745
 ethylketocyclozocine, 437, 733
 exifone, 253
 fenfluramine, 45, 291, 749
 fentanyl, 437
 FG 7142, 35, 425
 fluoxetine, 123
 haloperidol, 93, 159, 231, 283, 341, 399, 463
 heroin, 693
 8-hydroxy-2-(di-n-propylaminotetraline hydrobromide, 123
 8-hydroxy-2-(di-n-propylamino) tetralin, 625
 6-hydroxydopamine, 257
 ICI 118,551, 21
 ICI 154,129, 47
 idebenone, 351
 imipramine, 187, 359
 ketamine, 553
 ketanserin, 497, 701
 ketocyclazocine, 73
 lisuride, 93, 211
 lithium chloride, 437, 671
 LSD, 625
 mazindol, 291
 5-MeO-DMT, 625
 methadone, 437
 l-methadone, 73
 methamphetamine, 193
 3,4-methylenedioxymethamphetamine, 41
 methylphenidate, 513
 methioteplin, 93
 5-methoxy-N,N-dimethyl-tryptamine, 123
 metoclopramide, 165, 341
 morphine, 73, 87, 193, 437, 457, 611, 733
 muscimol, 45, 665, 745
 naloxone, 25, 73, 87, 525, 685
 naltrexone, 25, 529
 nicotine, 15, 505
 oxiracetam, 491
 oxotremorine, 723
 pargyline, 257
 pentobarbital, 323
 pentylenetetrazol, 99
 phencyclidine, 73, 323, 385
 phenobarbital, 171
 phentermine, 749
 phenylpropanolamine, 749
 physostigmine salicylate, 81
 pimozide, 67, 521
 $(-)$ -pindolol, 93
 pipamerone, 497
 piracetam, 253
 pirenperone, 93, 497
 propranolol, 35, 291
 pyridostigmine, 199
 pyridostigmine bromide, 81
 quinpirole, 93
 quipazine, 701
 reserpine, 21
 ritanserin, 497
 RO15-4513, 517
 Ro16-6028, 425
 Ro17-1812, 425
 RU 2496, 625
 RU24969, 497
 scopolamine, 253, 307, 483, 491, 569
 soman, 407
 sulpiride, 165, 239, 341, 399
 TAG, 235
 taurine, 235
 TFMPP, 625
 thioridazine, 399
 tiapride, 239
 trifluoperazine, 399
 U-50,488, 73, 477
 U-50,488H, 457
 vomitoxin, 247
 WR-2721, 573
 xylene, 653
 ZK 91296, 425
 ZK 93426, 35
- Drug comparisons
 d-amphetamine, 649
 l-amphetamine, 649
 anxiety, 171
 buspirone, 171
 B-HT 920, 283
 B-HT 933, 283
 clonidine, 283
 conflict behavior, 171
 diazepam, 171
 differential effects, 283
 dopaminergic substrate, 649
 dose-dependent effects, 733
 fixed consecutive number responding
 733
 food intake, 649
 kappa opioids, 733
 locomotor activity, 283
 methamphetamine, 193
 morphine, 193
 motor activity, horizontal, 193
 motor activity, vertical, 193
 mu opioids, 733
 naloxone, 73
 opiate agonists, 73
 phenobarbital, 171
 punished responding, 171
 rate of responding, 73
 sigma opioids, 733
 unpunished responding, 171
 wall climbing, 283
- Drug discrimination, 41
 isomeric comparisons
 3,4-methylenedioxymethamphetamine, 41
 time-course
- Drug interactions
 acetylcholine release, 491
 amnesia, 491
 d-amphetamine, 165
 aniracetam, 491
 antiaversive effects, 437
 anticholinergics, 81
 antiemetic effects, 437
 aversive effects, 437
 central nervous system, 323
 cholinergics, 81
 conditioned taste aversion, 81, 437
 depressants, 323
 ethanol, 235
 hypermotility, 165
 metoclopramide, 165
 mice/rat comparisons, 323
 opioid receptor agonists, 437
 oxiracetam, 491
 pharmacological antagonism, 81
 phencyclidine, 323
 route of administration, 165
 scopolamine, 491
 sleeptime, 235
 stereotypy, 165
 TAG, 235
 taurine, 235
 Drug reinforcement
 animal models, 385
 barbiturates, 391
 benzodiazepines, 391

- controlling factors, 367
 human/monkey/rodent comparisons, 391
 operant behavior, 367
 phencyclidine, 385
 phencyclnoids, 385
 route of administration, 391
 self-administration, 385, 391
- EEG-EMG addiction model**, 373
 opioid self-administration
 pharmacodynamic characteristics
 pharmacokinetic characteristics
- Ejaculation**, 187
 erection
 horses, males
 imipramine
 masturbation
 route of administration
 sexual behavior, male horses
- Electroconvulsive shock**, 217
 calcium antagonists
 cat brain
^{[3]H}nitrendipine binding
- Emotionality**, 569
 Digiscan activity
 locomotor activity
 stereotypic behavior measurement
 thigmotactic measurement
- Endogenous opioids**, 529
 conditional analgesia
 quaternary naltrexone
 stress-induced analgesia
- Enriched rearing**, 153
 forebrain
 6-hydroxydopamine
 isolation rearing
 neurobehavioral plasticity
 norepinephrine
- Environment-specific conditioning**, 61
 amphetamine
 horizontal activity
 sensitization
 vertical activity
- Environmental factors**, 379
 ethanol self-administration
 genetic factors
 strain differences
- Erection**, 187
 ejaculation
 horses, males
 imipramine
 masturbation
 route of administration
 sexual behavior, males horses
- Estradiol**
 castration, 265
 chemical delivery system, 265
 copulation, 265
 estrous cycle, 53
 footfaults, 53
 lisuride, 211
 lordosis, 211
 ovariectomy, 53, 211
 precopulatory patterns, 211
 rats, females, 211
 sensorimotor performance, 53
 sexual behavior, 211
 striatum, 53
- Estrogen**
 analgesia, 611
- catalepsy, 611
 dopamine, 93
 hyperactivity, 611
 inhibitory mechanisms, 93
 lordosis, 93
 morphine, 611
 ovariectomy, 611
 serotonin, 93
- Estrous cycle**, 53
 estradiol
 footfaults
 ovariectomy
 sensorimotor performance
 striatum
- Ethanol**
 aggression, 641
 aggression, female, 645
 attack, 641
 attack inhibition, 641
 central nervous system depression, 745
 chronic consumption, 333
 drug interaction, 235
 growth, 333
 intracranial self-stimulation, 15
 lactation, 333
 mammary gland composition, 333
 medial prefrontal cortex, 15
 metabolism, 333
 milk composition, 333
 milk production, 333
 muscimol, 745
 nicotine, 15
 opponent size, 645
 sleep time, 235, 745
 TAG, 235
 taurine, 235
- Ethanol preference**, 355
 depolarization-dependent Ca^{2+} uptake
 neurotransmission
- Ethanol reinforcement**, 517
 Ro15-4513
 self-administration
- Ethanol self-administration**, 379
 environmental factors
 genetic factors
 strain differences
- Ethanol stimulation**
 behavioral genetics, 577
 inbred mice, 421
 light/dark environment, 421
 motor activity, 421
 open field, 577
 pharmacogenetics, 577
 selective breeding, 577
- Ethanol treatments**, 665
 cerebellum, mouse
 chloride channels
 in vitro
- Exifone**, 253
 exploratory behavior
 passive avoidance
 rodent memory models
 scopolamine-induced amnesia
- Exploratory behavior**
 ambulation, 359
 anxiolytic agents, 239
 exifone, 253
 grooming, 359
 imipramine, chronic, 359
 novel environment, 359
 passive avoidance, 253
 rodent memory models, 253
- scopolamine-induced amnesia, 253
 social isolation, 359
 subchronic treatment, 239
 withdrawal, 239
- Extinction**, 205
 amphetamine
 continuous reinforcement
 nonreinforcement
 partial reinforcement
- Feed refusal**, 247
 conditioned taste aversion
 food consumption
 saccharin
 vomitoxin
- Fenfluramine**, 749
 acoustic startle
 diethylpropion
 phenetermine
 phenylpropanolamine
- Fixed-consecutive-number schedule**
 dose-dependent effects, 733
 drug comparisons, 73, 733
 kappa opioids, 733
 mu opioids, 733
 naloxone, 73
 opiate agonists, 73
 rate of responding, 73
 sigma opioids, 733
- Fixed ratio responding**, 653
 tolerance
 xylene inhalation
- Food competition**, 707
 d-amphetamine
 rats, males
- Food consumption**, 247
 conditioned taste aversion
 feed refusal
 saccharin
 vomitoxin
- Food deprivation**, 715
 catecholamine neurotransmitter
 2-deoxy-D-glucose
 lateral hypothalamus
 norepinephrine release
 satiety
- Food intake**
 d-amphetamine, 649
 l-amphetamine, 649
 amitriptyline, 105
 biogenic amine concentrations, 257
 body weight, 105
 catecholamine depletion, 257
 chickens, 257
 chicks, 25
 chronic administration, 105
 desipramine, 105
 dopaminergic substrate, 649
 drug comparisons, 649
 6-hydroxydopamine, 257
 opioid antagonists, 25
 tricyclic antidepressants, 105
 water intake, 25
- Food intake regulation**, 1
 dietary fat
 macronutrient selection
 monoamine oxidase
 serotonin metabolism
- Footfaults**, 53
 estradiol
 estrous cycle

- ovariectomy
- sensorimotor performance
- striatum
- Forebrain, 153
 - enriched rearing
 - 6-hydroxydopamine
 - isolation rearing
 - neurobehavioral plasticity
 - norepinephrine
- Gastric ulcers, stress-induced, 35
 - benzodiazepine receptor agonist
 - benzodiazepine receptor antagonist
- Genetic analysis, 87
 - hypothermia
 - morphine
 - naloxone
 - strain differences
- Genetic factors, 379
 - environmental factors
 - ethanol self-administration
 - strain differences
- Gerbils, 553
 - locomotor activity
 - N-methyl-D-aspartate
- Glucoprivic-feeding, 291
 - anorectic drugs
 - 2-deoxy-D-glucose
 - deprivation-induced feeding
 - site of action
- Grooming, 359
 - ambulation
 - exploratory behavior
 - imipramine, chronic
 - novel environment
 - social isolation
- Growth, 333
 - chronic consumption
 - ethanol
 - lactation
 - mammary gland composition
 - metabolism
 - milk composition
 - milk production
- Haloperidol
 - amphetamine, 231
 - ascorbic acid levels, 231
 - catalepsy, 159
 - conditioned avoidance behavior, 159
 - dopamine turnover, 159
 - in vivo*, 231
 - locomotor activity, 159
 - repeated testing, 159
 - treadmill, 159
 - uric acid levels, 231
- Heroin, 693
 - lateral hypothalamus
 - opiate antagonists
 - self-administration
- Horizontal activity, 61
 - amphetamine
 - environment-specific conditioning
 - sensitization
 - vertical activity
- Hormone
 - estradiol, 53, 93, 211, 223
 - estrogen, 53, 93, 611
 - insulin, 715
- norepinephrine, 153
- testosterone propionate, 223
- Horses, male, 189
 - ejaculation
 - erection
 - imipramine
 - masturbation
 - route of administration
 - sexual behavior, male horses
- 5-HT antagonists, 497
 - bin analysis
 - 5-HT receptors
 - lesions, 5,7-dihydroxytryptamine
 - locomotor activity
 - motor habituation
- 5-HT receptors
 - bin analysis, 497
 - 5-HT antagonists, 497
 - lesions, 5,7-dihydroxytryptamine, 497
 - locomotor activity, 497
 - memory, 625
 - motor habituation, 497
 - radial maze, 625
 - serotonergic agonists, 625
- Human/monkey/rodent comparisons, 391
 - barbiturates
 - benzodiazepines
 - drug reinforcement
 - route of administration
 - self-administration
- Human studies, 413
 - circadian rhythms
 - cortisol
 - mood ratings
 - stress
 - urine secretion
- Human studies, elderly adults, 273
 - cognitive tasks
 - diazepam
 - neuromotor skills
 - pharmacodynamics
- 6-Hydroxydopamine
 - biogenic amine concentrations, 257
 - catecholamine depletion, 257
 - chicks, 257
 - enriched rearing, 153
 - food intake, 257
 - forebrain, 153
 - isolation rearing, 153
 - neurobehavioral plasticity, 153
 - norepinephrine, 153
- Hyperactivity
 - analgesia, 611
 - Ca channels, 227
 - catalepsy, 611
 - diabetics, 227
 - estrogen, 611
 - median raphe nucleus, 45
 - morphine, 611
 - muscimol, 45
 - ovariectomy, 611
 - serotonin, 45
 - vasa deferentia, 227
- Hypermotility, 165
 - d-amphetamine
 - drug interactions
 - metoclopramide
 - route of administration
 - stereotypy
- Hypertonic saline intake, 425
 - benzodiazepine receptors
 - dehydration
- Hypocalcemia, 443
 - audiogenic seizures
 - magnesium deficiency
 - potassium levels
- Hypophsectomy, 629
 - dopamine behavior
 - dopamine receptors
- Hyporesponsiveness, 451
 - behavioral genetics
 - caffeine
 - DMCM
 - inbred mice
 - seizures, caffeine-induced
- Hypothalamus, 177
 - anatomical mapping
 - anorexia
 - calcitonin
- Hypothermia
 - $\beta 1$ adrenergic receptors, 21
 - $\beta 2$ adrenergic receptors, 21
 - genetic analysis, 87
 - morphine, 87
 - naloxone, 87
 - reserpine, 21
 - strain differences, 87
- Idebenone, 351
 - lesions, midbrain raphe nuclei
 - muricide
 - olfactory bulbectomy
- Imipramine, 187
 - ejaculation
 - erection
 - horses, males
 - masturbation
 - route of administration
 - sexual behavior, male horses
- Imipramine, chronic, 359
 - ambulation
 - exploratory behavior
 - grooming
 - novel environment
 - social isolation
- Inbred mice
 - behavioral genetics, 451
 - caffeine, 451
 - DMCM, 451
 - ethanol stimulation, 421
 - hyporesponsiveness, 451
 - light/dark environment, 421
 - motor activity, 421
 - seizures, caffeine-induced, 451
- Inbred strains, 317
 - alcohol preference
 - brain monoamines
- Inhibitory mechanisms, 93
 - dopamine
 - estrogen
 - lordosis
 - serotonin
- Intracerebral infusions, 183
 - calcitonin
 - locomotor activity, drug-induced
- Intracranial administration, 113
 - amphetamine
 - open field
 - stereotyped behavior
- Intracranial self-stimulation, 15
 - ethanol
 - medial prefrontal cortex
 - nicotine

- Intraperitoneal injection, 537
 brain extract
 paradoxical sleep inducing factor
- In vitro**, 665
 cerebellum, mouse
 chloride channels
 ethanol treatments
- In vivo**, 231
 amphetamine
 ascorbic acid levels
 haloperidol
 uric acid levels
- Isolation rearing, 153
 enriched rearing
 forebrain
 6-hydroxydopamine
 neurobehavioral plasticity
 norepinephrine
- Isomeric comparisons, 41
 drug discrimination
 3,4-methylenedioxymethamphetamine
 time-course
- Kappa opioids, 733
 dose-dependent effects
 drug comparisons
 fixed consecutive number responding
 mu opioids
 sigma opioids
- Lactation, 333
 chronic consumption
 ethanol
 growth
 mammary gland composition
 metabolism
 milk composition
 milk production
- Lateral hypothalamus
 catecholamine neurotransmitter, 715
 2-deoxy-D-glucose, 715
 food deprivation, 715
 heroin, 693
 norepinephrine release, 715
 opiate antagonists, 693
 satiety, 715
 self-administration, 693
- Learning/memory, 307
 autoshaping
 desglycinamide arginine vasopressin
 lever-touch response
 scopolamine
- Learning performance, 133
 ACTH_{4-10}
 long-term effects
 neonatal exposure
- Lesions, 5,7-dihydroxytryptamine, 497
 bin analysis
 5-HT antagonists
 5-HT receptors
 locomotor activity
 motor habituation
- Lesions, dorsal raphe nucleus, 123
 antimuricidal effect
 p-chlorophenylalanine
 dorsal raphe nucleus
 lesions, electrolytic
 lesions, median raphe nucleus
 median raphe nucleus
- mouse killing behavior
 serotonin-mimetic drugs
 serotonin neurotransmission
- Lesions, electrical, 457
 analgesia
 dopaminergic system
 morphine
 U-50,488H
- Lesions, electrolytic, 123
 antimuricidal effect
 p-chlorophenylalanine
 dorsal raphe nucleus
 lesions, dorsal raphe nucleus
 lesions, median raphe nucleus
 median raphe nucleus
 mouse killing behavior
 serotonin-mimetic drugs
 serotonin neurotransmission
- Lesions, median raphe nucleus, 123
 antimuricidal effect
 p-chlorophenylalanine
 dorsal raphe nucleus
 lesions, dorsal raphe nucleus
 lesions, electrolytic
 median raphe nucleus
 mouse killing behavior
 serotonin-mimetic drugs
 serotonin neurotransmission
- Lesions, midbrain raphe nuclei, 351
 idebenone
 muricide
 olfactory bulbectomy
- Lethality, 299
 CNS stimulants
 DRL performance
 "look-alike" stimulants
 stimulant interaction
- Lever pressing, 67
 anhedonia
 pimozide
 rats, nondeprived
 sucrose reward
- Lever-touch response, 307
 autoshaping
 desglycinamide arginine vasopressin
 learning/memory
 scopolamine
- Light/dark environment, 421
 ethanol stimulation
 inbred mice
 motor activity
- Lisuride, 211
 estradiol
 lordosis
 ovariectomy
 precopulatory patterns
 rats, females
 sexual behavior
- Lithium chloride, 671
 combined treatment
 conditioned taste aversion
 radiation
- Locomotor activity
 age differences, 545
 bin analysis, 497
 B-HT 920, 283
 B-HT 933, 283
 catalepsy, 159
 clonidine, 283
 conditioned avoidance behavior, 159
 data management, 545
 day-night nociception, 477
- differential effects, 283
 Digiscan activity, 569
 dopamine turnover, 159
 dose response, 573
 drug comparisons, 283
 emotionality, 569
 gerbils, 553
 haloperidol, 159
 5-HT antagonists, 497
 5-HT receptors, 497
 lesions, 5,7-dihydroxytryptamine, 497
 N-methyl-D-aspartate, 553
 microcomputer, 545
 motor habituation, 497
 neural transplantation, 583
 opiate agonists, 477
 radioprotection, 573
 repeated testing, 159
 sex differences, 477
 stereotypic behavior measurement, 569
 striatum, 583
 thigmotactic measurement, 569
 time relationship, 573
 treadmill, 159
 wall climbing, 283
 WR-2721, 573
- Locomotor activity, drug-induced, 183
 calcitonin
 intracerebral infusions
- Long-term administration, 399
 antipsychotic drugs
 body weight
 caloric intake
 D2 receptors
 dose-dependent effects
 male/female comparisons
- Long-term effects
 ACTH_{4-10} , 133
 behavioral sensitivity, 99
 diazepam, 99
 learning performance, 133
 neonatal exposure, 133
 pentylenetetrazol, 99
 stress, 99
 "Look-alike" stimulants, 299
 CNS stimulants
 DRL performance
 lethality
 stimulant interaction
- Lordosis
 dopamine, 93
 estradiol, 211
 estrogen, 93
 inhibitory mechanisms, 93
 lisuride, 211
 ovariectomy, 211
 precopulatory patterns, 211
 rats, females, 211
 serotonin, 93
 sexual behavior, 211
- Macronutrient selection, 1
 dietary fat
 food intake regulation
 monoamine oxidase
 serotonin metabolism
- Magnesium deficiency, 443
 audiogenic seizures
 hypocalcemia
 potassium levels

- Male/female comparisons**, 399
 antipsychotic drugs
 body weight
 caloric intake
 D2 receptors
 dose-dependent effects
 long term administration
- Mammary gland composition**, 333
 chronic consumption
 ethanol
 growth
 lactation
 metabolism
 milk composition
 milk production
- Masturbation**, 187
 ejaculation
 erection
 horses, males
 imipramine
 route of administration
 sexual behavior, male horses
- Medial prefrontal cortex**, 15
 ethanol
 intracranial self-stimulation
 nicotine
- Median raphe nucleus**
 antimuricidal effect, 123
 p-chlorophenylalanine, 123
 dorsal raphe nucleus, 123
 hyperactivity, 45
 lesions, dorsal raphe nucleus, 123
 lesions, electrolytic, 123
 lesions, median raphe nucleus, 123
 mouse killing behavior, 123
 muscimol, 45
 serotonin, 45
 serotonin-mimetic drugs, 123
 serotonin neurotransmission, 123
- Memory**, 625
 5-HT receptors
 radial maze
 serotonergic agonists
- Metabolism**, 333
 chronic consumption
 ethanol
 growth
 lactation
 mammary gland composition
 milk composition
 milk production
- Methamphetamine**, 193
 drug comparisons
 morphine
 motor activity, horizontal
 motor activity, vertical
- Method**
 gas chromatography, 491
 Hebb-William maze, 153
 isobolographic analysis, 323
 Lashley maze, 153
 lever press, 513
 voltammetry, 231
- N-Methyl-D-aspartate**, 553
 gerbils
 locomotor activity
- 3,4-Methylenedioxymethamphetamine**, 41
 drug discrimination
 isomeric comparisons
 time-course
- Methylphenidate**, 513
- d-amphetamine
 timing
- Metoclopramide**, 165
 d-amphetamine
 drug interactions
 hypermotility
 route of administration
 stereotypy
- Mice/rat comparisons**, 323
 central nervous system
 depressants
 drug interactions
 phencyclidine
- Microcomputer**, 545
 age differences
 data management
 locomotor activity
- Microwaves**, 635
 choline uptake
 classical conditioning
 tolerance
- Milk composition**, 333
 chronic consumption
 ethanol
 growth
 lactation
 mammary gland composition
 metabolism
 milk production
- Milk production**, 333
 chronic consumption
 ethanol
 growth
 lactation
 mammary gland composition
 metabolism
 milk composition
- Monkeys**, dominant, 701
 monkeys, subordinate
 serotonin receptor sites
- Monkeys**, subordinate, 701
 monkeys, dominant
 serotonin receptor sites
- Monoamine oxidase**, 1
 dietary fat
 food intake regulation
 macronutrient selection
 serotonin metabolism
- Mood ratings**, 413
 circadian rhythms
 cortisol
 human studies
 stress
 urine secretion
- Morphine**
 analgesia, 457, 611
 catalepsy, 611
 dopaminergic system, 457
 drug comparisons, 193
 estrogen, 611
 genetic analysis, 87
 hyperactivity, 611
 hypothermia, 87
 lesions, electrical, 457
 methamphetamine, 193
 motor activity, horizontal, 193
 motor activity, vertical, 193
 naloxone, 87
 ovariectomy, 611
 strain differences, 87
 U-50,488H, 457
- Morphine analgesia**, 525
 cold-water swim analgesia
 naloxone, chronic
- Motor activity**, 421
 ethanol stimulation
 inbred mice
 light/dark environment
- Motor activity, horizontal**, 193
 drug comparisons
 methamphetamine
 morphine
 motor activity, vertical
- Motor activity, vertical**, 193
 drug comparisons
 methamphetamine
 morphine
 motor activity, horizontal
- Motor deficit**, 341
 anhedonia
 consummatory behaviors
 neuroleptics
 operant behaviors
- Motor habituation**, 497
 bin analysis
 5-HT antagonists
 5-HT receptors
 lesions, 5,7-dihydroxytryptamine
 locomotor activity
- Mu opioids**, 733
 dose-dependent effects
 drug comparisons
 fixed consecutive number responding
 kappa opioids
 sigma opioids
- Muricide**
 antimuricidal effect, 123
 p-chlorophenylalanine, 123
 dorsal raphe nucleus, 123
 idebenone, 351
 lesions, dorsal raphe nucleus, 123
 lesions, electrolytic, 123
 lesions, median raphe nucleus, 123
 lesions, midbrain raphe nuclei, 351
 median raphe nucleus, 123
 olfactory bulbectomy, 351
 serotonin-mimetic drugs, 123
 serotonin neurotransmission, 123
- Muscarinic binding**, 143
 chronic treatment
 diisopropylfluorophosphate
 spatial learning
- Muscarinic receptor levels**, 723
 oxotremorine, chronic
 strain differences
 tolerance
- Muscimol**
 central nervous system depression, 745
 ethanol, 745
 hyperactivity, 45
 median raphe nucleus, 45
 serotonin, 45
 sleep time, 745
- Naloxone**
 drug comparisons, 73
 fixed-consecutive number schedule, 73
 genetic analysis, 87
 hypothermia, 87
 morphine, 87
 opiate agonists, 73

- rate of responding, 73
- strain differences, 87
- Naloxone**, chronic, 525
 - cold-water swim analgesia
 - morphine angesia
- Neonatal exposure**, 133
 - ACTH_{4-10}
 - learning performance
 - long-term effects
- Neural transplantation**, 583
 - locomotor activity
 - striatum
- Neurobehavioral plasticity**, 153
 - enriched rearing
 - forebrain
 - 6-hydroxydopamine
 - isolation rearing
 - norepinephrine
- Neuroleptics**, 341
 - anhedonia
 - consummatory behaviors
 - motor deficit
 - operant behaviors
- Neuromotor skills**, 273
 - cognitive tasks
 - diazepam
 - human studies, elderly adults
 - pharmacodynamics
- Neurotransmission**, 355
 - depolarization-dependent Ca^{2+} uptake
 - ethanol preference
- Nicotine**
 - ethanol, 15
 - intracranial self-stimulation, 15
 - medial prefrontal cortex, 15
 - receptor levels, 505
 - tolerance development, 505
- Nipple attachment**, 7
 - age differences
 - body weight
 - serotonin
- [³H]Nitrendipine binding, 217
 - calcium antagonists
 - cat brain
 - electroconvulsive shock
- Nonreinforcement**, 205
 - amphetamine
 - continuous reinforcement
 - extinction
 - partial reinforcement
- Norepinephrine**, 153
 - enriched rearing
 - forebrain
 - 6-hydroxydopamine
 - isolation rearing
 - neurobehavioral plasticity
- Norepinephrine release**, 715
 - catecholamine neurotransmitter
 - 2-deoxy-D-glucose
 - food deprivation
 - lateral hypothalamus
 - satiety
- Novel environment**
 - ambulation, 359
 - clonidine, 659
 - consummatory negative contrast, 659
 - exploratory behavior, 359
 - grooming, 359
 - imipramine, chronic, 359
 - social isolation, 359
 - stress, 659
- Olfactory bulbectomy**, 351
 - idebenone
 - lesions, midbrain raphe nuclei
 - muricide
- Open field activity**
 - amphetamine, 113
 - behavioral changes, 407
 - behavioral genetics, 577
 - ethanol stimulation, 577
 - intracranial administration, 113
 - organophosphate exposure, 407
 - pharmacogenetics, 577
 - selective breeding, 577
 - stereotyped behavior, 113
 - T-maze learning, 407
- Operant behaviors**
 - anhedonia, 341
 - consummatory behaviors, 341
 - controlling factors, 367
 - drug reinforcement, 367
 - motor deficit, 341
 - neuroleptics, 341
 - self-administration, 367
- Opiate agonists**
 - day-night nociception, 477
 - drug comparisons, 73
 - fixed-consecutive number schedule, 73
 - locomotor activity, 477
 - naloxone, 73
 - rate of responding, 73
 - sex differences, 477
- Opiate antagonists**, 693
 - heroin
 - lateral hypothalamus
 - self-administration
- Opioid antagonists**, 25
 - chickens
 - food intake
 - water intake
- Opioid receptor agonists**, 437
 - antiaversive effects
 - antiemetic effects
 - aversive effects
 - conditioned taste aversion
 - drug interaction
- Opioid self-administration**, 373
 - EEG-EMG addiction model
 - pharmacodynamic characteristics
 - pharmacokinetic characteristics
- Opponent size**, 645
 - aggression, female
 - ethanol
- Organophosphate exposure**, 407
 - behavioral changes
 - open field activity
 - T-maze learning
- Osmotic pump**, 199
 - blood serum cholinesterase
 - premature release
 - pyridostigmine
- Ovariectomy**
 - analgesia, 611
 - catalepsy, 611
 - estradiol, 53, 211
 - estrogen, 611
 - estrous cycle, 53
 - footfaults, 53
 - hyperactivity, 611
 - lisuride, 211
 - lordosis, 211
 - morphine, 611
 - precopulatory patterns, 211
- rats, females**, 211
- sensorimotor performance**, 53
- sexual behavior**, 211
- striatum**, 53
- Oxiracetam**, 491
 - acetylcholine release
 - amnesia
 - aniracetam
 - drug interactions
 - scopolamine
- Oxotremorine**, chronic, 723
 - muscarinic receptor levels
 - strain differences
 - tolerance
- Paradoxical sleep inducing factor**, 537
 - brain extract
 - intraperitoneal injection
- Partial reinforcement**, 205
 - amphetamine
 - continuous reinforcement
 - extinction
 - nonreinforcement
- Passive avoidance**, 253
 - exifone
 - exploratory behavior
 - rodent memory models
 - scopolamine-induced amnesia
- Pattern analysis**, 559
 - automated behavior observation
- Pentylenetetrazol**, 99
 - behavioral sensitivity
 - diazepam
 - long-term effects
 - stress
- Peptide**
 - ACTH_{1-10} , 133
 - calcitonin, 177, 183
 - corticotropin-releasing factor, 685
 - desglycinamide arginine vasopressin 307
 - [D-Ala², Met⁵]enkephalinamide, 437
 - [Leu⁵]enkephalin, 437
 - serotonin, 45
- Pharmacodynamic characteristics**, 373
 - EEG-EMG addiction model
 - opioid self-administration
 - pharmacokinetic characteristics
- Pharmacodynamics**, 273
 - cognitive tasks
 - diazepam
 - human studies, elderly adults
- Pharmacogenetics**, 577
 - behavioral genetics
 - ethanol stimulation
 - open field
 - selective breeding
- Pharmacokinetic characteristics**, 373
 - EEG-EMG addiction model
 - opioid self-administration
 - pharmacodynamic characteristics
- Pharmacological antagonism**, 81
 - anticholinergics
 - cholinergics
 - conditioned taste aversion
 - drug interaction
- Phencyclidine**
 - animal models, 385
 - central nervous system, 323
 - depressants, 323
 - drug interactions, 323

- drug reinforcement, 385
 mice/rat comparisons, 323
 phencyclinoids, 385
 self-administration, intravenous, 385
Phencyclinoids, 385
 animal models
 drug reinforcement
 phencyclidine
 self-administration, intravenous
Phenobarbital, 171
 anxiety
 buspirone
 conflict behavior
 diazepam
 drug comparisons
 punished responding
 unpunished responding
Phentermine, 749
 acoustic startle
 diethylpropion
 fenfluramine
 phenylpropanolamine
Phenylpropanolamine, 749
 acoustic startle
 diethylpropion
 fenfluramine
 phentermine
Pimozide
 anhedonia, 67
 dopamine-receptor blockade, 521
 lever pressing, 67
 rats, nondeprived, 67
 stimulation-induced feeding, 521
 sucrose reward, 67
Plasma corticosterone, 619
 brain 5-HT levels
 diazepam
 stress
Potassium-levels, 443
 audiogenic seizures
 hypocalcemia
 magnesium deficiency
Precopulatory patterns, 211
 estradiol
 lisuride
 lordosis
 ovariectomy
 rats, females
 sexual behavior
Premature release, 199
 blood serum cholinesterase
 osmotic pump
 pyridostigmine
Punished responding, 171
 anxiety
 buspirone
 conflict behavior
 diazepam
 drug comparisons
 phenobarbital
 unpunished responding
Pyridostigmine, 199
 blood serum cholinesterase
 osmotic pump
 premature release
Quaternary naltrexone, 529
 conditioned analgesia
 endogenous opioids
 stress-induced analgesia
Radial maze performance
 acquisition, 483
 5-HT receptors, 625
 memory, 625
 scopolamine, 483
 serotonergic agonists, 625
 spatial memory, 483
 strain differences, 483
Radiation
 amphetamines, 677
 area postrema, 677
 combined treatment, 671, 677
 conditioned taste aversion, 671, 677
 lithium chloride, 671
Radioprotection, 573
 dose response
 locomotor activity
 time relationship
 WR-2721
Rate of responding, 73
 drug comparisons
 fixed-consecutive-number schedule
 naloxone
 opiate agonists
Rats, female, 211
 estradiol
 lisuride
 lordosis
 ovariectomy
 precopulatory patterns
 sexual behavior
Rats, male, 707
 d-amphetamine
 food competition
Rats, nondeprived, 67
 anhedonia
 lever pressing
 pimozide
 sucrose reward
Receptor levels, 505
 nicotine
 tolerance development
Rehydration, 425
 benzodiazepine receptors
 hypertonic saline intake
Reliabilities, 565
 automated monitor
 behavioral measures
 spontaneous motor activity
 time course
Repeated testing, 159
 catalepsy
 conditioned avoidance behavior
 dopamine turnover
 haloperidol
 locomotor activity
 treadmill
Reserpine, 21
 β_1 adrenergic receptors
 β_2 adrenergic receptors
 hypothermia
RO15-4513, 517
 ethanol reinforcement
 self-administration
Rodent memory models, 253
 exifone
 exploratory behavior
 passive avoidance
 scopolamine-induced amnesia
Route of administration
 d-amphetamine, 165
 barbiturates, 391
benzodiazepines, 391
 drug interactions, 165
 drug reinforcement, 391
 ejaculation, 187
 erection, 187
 horses, males, 187
 human/monkey/rodent comparisons, 391
 hypermotility, 165
 imipramine, 187
 masturbation, 187
 metoclopramide, 165
 self-administration, 391
 sexual behavior, male horses, 187
 stereotypy, 165
Saccharin, 247
 conditioned taste aversion
 feed refusal
 food consumption
 vomitoxin
Satiety, 715
 catecholamine neurotransmitter
 2-deoxy-D-glucose
 food deprivation
 lateral hypothalamus
 norepinephrine release
Schedule-induced polydipsia, 463
 bar-pressing
 dopamine agents
 drinking
 water deprivation
Scopolamine
 acetylcholine release, 491
 acquisition, 483
 amnesia, 491
 aniracetam, 491
 autoshaping, 307
 desglycinamide arginine vasopressin 307
 drug interactions, 491
 learning/memory, 307
 lever-touch response, 307
 oxiracetam, 491
 radial maze performance, 483
 spatial memory, 483
 strain differences, 483
Scopolamine-induced amnesia, 253
 exifone
 exploratory behavior
 passive avoidance
 rodent memory models
Seizures, caffeine-induced, 451
 behavioral genetics
 caffeine
 DMCM
 hyporesponsiveness
 inbred mice
Selective breeding, 577
 behavioral genetics
 ethanol stimulation
 open field
 pharmacogenetics
Self-administration
 barbiturates, 391
 benzodiazepines, 391
 controlling factors, 367
 drug reinforcement, 367, 391
 ethanol reinforcement, 517
 heroin, 693

- human/monkey/rodent comparisons, 391
 lateral hypothalamus, 693
 operant behavior, 367
 opiate antagonists, 693
 RO15-4513, 517
 route of administration, 391
Self-administration, intravenous, 385
 animal models
 drug reinforcement
 phencyclidine
 phencyclonoids
Sensitization
 amphetamine, 61
 cocaine, 533
 dopamine release, 533
 environment-specific conditioning, 61
 horizontal activity, 61
 vertical activity, 61
Sensorimotor performance, 53
 estradiol
 estrous cycle
 footfaults
 ovariectomy
 striatum
Serotonin
 age differences, 7
 body weight, 7
 dopamine, 93
 estrogen, 93
 hyperactivity, 45
 inhibitory mechanisms, 93
 lordosis, 93
 median raphe nucleus, 45
 muscimol, 45
 nipple attachment, 7
Serotonergic agonists, 625
 5-HT receptors
 memory
 radial maze
Serotonin metabolism, 1
 dietary fat
 food intake regulation
 macronutrient selection
 monoamine oxidase
Serotonin-mimetic drugs, 123
 antimuricidal effect
 p-chlorophenylalanine
 dorsal raphe nucleus
 lesions, dorsal raphe nucleus
 lesions, electrolytic
 lesions, median raphe nucleus
 lesions, electrolytic
 lesions, median raphe nucleus
 median raphe nucleus
 mouse killing behavior
 serotonin neurotransmission
Serotonin neurotransmission, 123
 antimuricidal effect
 p-chlorophenylalanine
 dorsal raphe nucleus
 lesions, dorsal raphe nucleus
 lesions, electrolytic
 lesions, median raphe nucleus
 median raphe nucleus
 mouse killing behavior
 serotonin-mimetic drugs
Serotonin receptor sites, 701
 monkeys, dominant
 monkeys, subordinate
Sex differences
 adiposity, 223
 castration, 223
 chickens, 223
 day-night nociception, 477
 locomotor activity, 477
 opiate agonists, 477
 strain differences, 223
 testosterone, 223
Sexual behavior, 211
 estradiol
 lisuride
 lordosis
 ovariectomy
 precopulatory behavior
 rats, females
Sexual behavior, male horses, 187
 ejaculation
 erection
 horses, males
 imipramine
 masturbation
 route of administration
Sigma opioids, 733
 dose-dependent effects
 drug comparisons
 fixed consecutive number responding
 kappa opioids
 mu opioids
Site of action, 291
 anorectic drugs
 2-deoxy-D-glucose
 deprivation-induced feeding
 glucoprivive-feeding
Sleep time
 central nervous system depression, 745
 drug interaction, 235
 ethanol, 235, 745
 muscimol, 745
 TAG, 235
 taurine, 235
Social isolation, 359
 ambulation
 exploratory behavior
 grooming
 imipramine, chronic
 novel environment
Spatial learning, 143
 chronic treatment
 diisopropylfluorophosphate
 muscarinic binding
Spatial memory, 483
 acquisition
 radial maze performance
 scopolamine
 strain differences
Spontaneous motor activity, 565
 automated monitor
 behavioral measures
 reliabilities
 time course
Stereotyped behavior
 amphetamine, 113
 d-amphetamine, 165
 drug interactions, 165
 hypermotility, 165
 intracranial administration, 113
 metoclopramide, 165
 open field, 113
 route of administration, 165
Stereotypic behavior measurement, 569
 Digiscan activity
 emotionality
 locomotor activity
 thigmotactic measurement
Stimulant interaction, 299
 CNS stimulants
 DRL performance
 lethality
 "look-alike" stimulants
Stimulation-induced feeding, 521
 dopamine-receptor blockade
 pimozide
Strain differences
 acquisition, 483
 adiposity, 223
 castration, 223
 chickens, 223
 environmental factors, 379
 ethanol self-administration, 379
 genetic analysis, 87
 genetic factors, 379
 hypothermia, 87
 morphine, 87
 muscarinic receptor levels, 723
 naloxone, 87
 oxotremorine, chronic, 723
 radial maze performance, 483
 scopolamine, 483
 sex differences, 223
 spatial memory, 483
 testosterone, 223
 tolerance, 723
Stress
 behavioral sensitivity, 99
 brain 5-HT levels, 619
 cerebral catecholamine systems, 685
 circadian rhythms, 413
 clonidine, 659
 consummatory negative contrast, 659
 corticotropin-releasing factor, 685
 cortisol, 413
 diazepam, 99, 619
 human studies, 413
 long-term effects, 99
 mood ratings, 413
 novel environment, 659
 pentylenetetrazol, 99
 plasma corticosterone, 619
 urine secretion, 413
Stress-induced analgesia, 529
 conditioned analgesia
 endogenous opioids
 quaternary naltrexone
Striatum
 estradiol, 53
 estrous cycle, 53
 footfaults, 53
 locomotor activity, 583
 neural transplantation, 583
 ovariectomy, 53
 sensorimotor performance, 53
Subchronic treatment, 239
 anxiolytic agents
 exploratory behavior
 withdrawal
Sucrose reward, 67
 anhedonia
 lever pressing
 pimozide
 rats, nondeprived
 TAG, 235
 drug interaction

ethanol	nicotine, 505	Vasa deferentia, 227
sleep time	oxotremorine, chronic, 723	Ca channels
taurine	receptor levels, 505	diabetics
Taurine, 235	strain differences, 723	hyperactivity
drug interaction	xylene inhalation, 653	Vertical activity, 61
ethanol	Treadmill, 159	amphetamine
sleep time	catalepsy	environment-specific conditioning
TAG	conditioned avoidance behavior	horizontal activity
Testosterone, 223	dopamine turnover	sensitization
adiposity	haloperidol	Vomitoxin, 247
castration	locomotor activity	conditioned taste aversion
chickens	repeated testing	feed refusal
sex differences	Tricyclic antidepressants, 105	food consumption
strain differences	amytriptyline	saccharin
Thigmotactic measurement, 569	body weight	Wall-climbing, 283
Digiscan activity	chronic administration	B-HT 920
emotionality	desipramine	B-HT 933
locomotor activity	food intake	clonidine
stereotypic behavior measurement	U-50,488H, 457	differential effects
Time course	analgesia	drug comparisons
automated monitor, 565	dopaminergic system	locomotor activity
behavioral measures, 565	lesions, electrical	Water deprivation, 463
drug discrimination, 41	morphine	bar pressing
isomeric comparisons, 41	Unpunished responding, 171	dopamine agents
3,4-methylenedioxymethamphetamine, 41	anxiety	drinking
reliabilities, 565	buspirone	schedule-induced polydipsia
spontaneous motor activity, 565	conflict behavior	Water intake, 25
Time relationship, 573	diazepam	chickens
dose response	drug comparisons	food intake
locomotor activity	phenobarbital	opioid antagonists
radio protection	punished responding	Withdrawal, 239
WR-2721	Uric acid levels, 231	anxiolytic agents
Timing, 513	amphetamine	exploratory behavior
d-amphetamine	ascorbic acid levels	subchronic treatment
methylphenidate	haloperidol	WR-2721, 573
T-maze learning, 407	in vivo	dose response
behavioral changes	Urine secretion, 413	locomotor activity
open field activity	circadian rhythms	radio protection
organophosphate exposure	cortisol	time relationship
Tolerance	human studies	Xylene inhalation, 653
choline uptake, 635	mood ratings	fixed ratio responding
classical conditioning, 635	stress	tolerance
fixed ratio responding, 653		
microwaves, 635		
muscarinic receptor levels, 723		

AUTHOR INDEX

Abla, K. A., 451	Beninger, R. J., 61	Calcagnetti, D. J., 529	Crane, S. B., 1
Ahlenius, S., 93, 159	Bercovitz, H., 205	Carney, J. M., 451	Crawley, J. N., 291
Allan, A. M., 665	Berka, C., 133	Carr, G. D., 113	Davidson, T. L., 99
Allen, J. D., 463	Berridge, C. W., 685	Chaistitwanich, R., 443	Davis, H. D., 573
Anderson, W. R., 265	Bird, D. C., 299	Chen, C. H., 193	de Beaurepaire, R., 177, 183
Angel, I., 291	Blanchard, D. C., 641, 645	Chou, C. K., 635	Demetrikopoulos, M. K., 659
Arregui-Aguirre, A., 15	Blanchard, R. J., 641, 645	Ciesielski, L., 123	Denbow, D. M., 25
Asin, K. E., 45	Blancquaert, J.-P., 437	Clancy, A. N., 133	Dumont, G., 253
Ator, N. A., 391	Boast, C. A., 543, 553	Clark, D. E., 247	Deutsch, C. M., 577
Avril, I., 253	Bodnar, R. J., 525	Claro-Izaguirre, F., 15	Dominitz, J. A., 573
Bacher, J., 217	Bodor, N., 265	Collins, A. C., 505, 723	Dubow, D., 273
Balfour, D. J. K., 619	Boggan, W. O., 421	Commissaris, R. L., 171	Dunn, A. J., 685
Balster, R. L., 323	Bolger, G. T., 217	Cooper, S. J., 425	Dykstra, L. A., 73
Baptista, T., 399	Bozarth, M. A., 521	Copeland, R. L., Jr., 653	Eckerman, D. A., 513
Barry, J. M., 239	Brammer, G. L., 701	Copland, A. M., 619	Ellinwood, E. H., Jr., 273
Bassett, J. R., 413	Breese, G. S., 513	Corrigall, W. A., 693	Evans, K. R., 649
Becker, J. B., 53	Brewster, M. E., 265	Coscina, D. V., 105	Fan, T., 355
Beckwith, B. E. 133	Bronson, M. E., 733	Costall, B., 239	
Bednarik, E. J., 569	Bushnell, P. J., 431	Crabbe, J. C., 577	
		Craft, R. M., 165	

- Fanselow, M. S., 529
 Feldon, J., 205
 Ferko, A. P., 235, 745
 Fernández-Guasti, A., 93
 Finnefrock, J. A., 569
 Flaherty, C. F., 659
 Flannelly, K., 645
 Forster, M. M., 545
 Fowler, C. J., 159
 Fowler, S. C., 67
 Francès, H., 21
 Freed, W. J., 177, 183
- Garcia, M. C., 187
 George, F. R., 365, 379
 Ghosh, T. K., 653
 Ginter, H., 35
 Gobaille, S., 123
 Goñi-Garrido, M. J., 15
 Goodlett, C. R., 283
 Gordon, C. J., 431
 Gramling, S. E., 67
 Greenwood, C. E., 1
 Griffiths, R. R., 391
 Grigson, P. S., 659
 Gurson, D. B., 569
 Guy, A. W., 635
 Gvaryahu, G., 223
- Hagenmeyer-Houser, S. H., 583
 Hall, J., 641, 645
 Harkabus, L. J., 569
 Harris, R. A., 665
 Hartgraves, S. L., 199
 Harvey, R. B., 247
 Haskett, C., 231
 Heatherly, D. G., 273
 Heise, J. W., 73
 Helmstetter, F. J., 529
 Hendricks, D. G., 443
 Hernandez, L., 399
 Herrera, E., 333
 Higashida, A., 483
 Hillegaart, V., 159
 Hjorth, S., 93
 Hliňák, Z., 211
 Holloway, F. A., 299
 Honda, H., 227
 Hopper, D. L., 559
 Hori, K., 641, 645
 Horita, A., 635
 Howard, J. L., 165
 Hruska, R. E., 629
 Huerta, P. L., 299
 Hughes, R. N., 359
 Hughey, D., 407
 Hunt, W. A., 671, 677
- Ings, R., 153
 Innes, D. G. L., 477
 Inturrisi, C. E., 525
 Isaac, L., 217
 Isel, F., 123
 Itoh, T., 193
 Iwamoto, E. T., 307
- Jappay, E., 497
 Jenks, J. A., 569
 Jenuwine, M. J., 53
- Kato, R., 87
 Kavaliers, M., 477
 Kazandjian, A., 611
 Kelly, M. E., 239
 Kenney, R. M., 187
 Kerenyi, S. Z., 199
 Kernan, W. J., Jr., 559
 Kest, B., 525
 Khazan, N., 365, 373
 King, J. M., 81
 Klitenick, M. A., 45
 Komura, S., 317
 Kosobud, A., 577
 Kreider, M., 7
 Kuenzel, W. J., 257
 Kutscher, C. L., 749
- LaForest, A. R., 569
 Lai, H., 635
 Landauer, M. R., 573
 Larsson, K., 93
 Lee, J., 671, 677
 Lefebvre, R. A., 437
 Lenègre, A., 253
 Lerma, M. S., 247
 Leshem, M., 7
 Lewis, R. M., 707
 Ljungberg, T., 341
 Lucki, I., 99
- McCloskey, T. C., 171
 McCormack, J. F., 25
 McDonnell, S. M., 187
 McDonough, J., 407
 McGivern, R. F., 133
 McGuire, M. T., 701
- MacRae, L. K., 565
 Magnusson, O., 159
 Mahoney, A. W., 443
 Mandel, P., 123
 Manning, S., 513
 Marks, M. J., 505, 723
 Marquis, K. L., 385
 Masuda, Y., 193
 Matthies, H., 537
 Mattucci-Schiavone, L., 745
 Mazurski, E. J., 61
 Meisch, R. A., 367
 Michaelis, R. C., 299
 Middaugh, L. D., 421
 Miller, M. M., 53
 Mills, F. G., 517
 Mitchell, J. A., 707
 Mitchell, S. G., 569
 Miyamoto, M., 351
 Modrow, H., 407
 Moerschbaecher, J. M., 733
 Molina, V., 123
 Mookherjee, S., 653
 Moreton, J. E., 385
- Morgado-Bernal, I., 15
 Mueller, K., 231
 Mullenix, P. J., 559
 Mundy, W. R., 307
 Murai, S., 193
 Muraki, T., 87
 Murtha, S., 153
 Myers, R. D., 715
- Nagaoka, A., 351
 Nagy, R. P., 569
 Naranjo, C. A., 355
 Naylor, R. J., 239
 Nikaido, A. M., 273
 Nobrega, J. N., 105
 Nomikos, G., 611
- Ogawa, N., 483
 Ohno, M., 457
 Olton, D., 407
 Ossenkopp, K.-P., 565
- Pappas, B. A., 153
 Parada, M., 399
 Parui, R. N., 653
 Pastor, G., 553
 Paul, B. K., 171
 Paul, S. M., 291
 Peinado, J. M., 715
 Pepeu, G., 491
 Peris, J., 533
 Petti, D. T., 625
 Pfeffer, A. O., 517
 Picker, M., 73
 Pither, J. M., 359
 Pollard, G. T., 165
 Porsolt, R. D., 253
 Pradhan, S. N., 653
 Pranzatelli, M. R., 497
- Rabin, B. M., 671, 677
 Raffaele, K., 407
 Raleigh, M. J., 701
 Randall, C. L., 421
 Remesar, X., 333
 Renner, O. M., 451
 Rexroad, C. E., Jr., 257
 Rhoads, K., 569
 Robinzon, B., 223
 Roderick, T. H., 451
 Rohrbach, K. W., 165
 Romano, J. A., 81
 Romm, E., 723
 Rose, G., 133
 Rozenboim, I., 223
- Saari, M., 153
 Sadeghi, K. G., 517
 Saito, H., 193
 Sakai, Y., 227
 Samson, H. H., 517
 Sanberg, P. R., 543, 569, 583
 Sandman, C. A., 133
 Sayag, N., 223
 Schechter, M. D., 41
- Seale, T. W., 451
 Segbefia, D., 513
 Sfikakis, A., 611
 Simon, P., 21
 Simpkins, J. W., 265
 Sisson, D. V., 443
 Skolnick, P., 35
 Smythe, J., 153
 Snapir, N., 223, 257
 Snodgrass, S. H., 463, 497
 Snyder, P. J., 53
 Spignoli, G., 491
 Spillane, R., 413
 Spyrali, C., 611
 Stange, K., 153
 Stark, H., 537
 Stéru, L., 253
 Stitzel, J. A., 505
 Stivers, J. A., 291
 Streather, A., 521
- Tam, B. R., 577
 Teskey, G. C., 565
 Ticarich, C. D., 569
 Tizzano, J. P., 67
 Tolliver, G. A., 517
 Truesdell, L. S., 525
 Trullas, R., 35
- Ueki, S., 457
 Upchurch, M., 143
- Vaccarino, F. J., 649
 Valentino, M. L., 283
 Van Arsdalen, K. N., 187
 Vilaró, S., 333
 Viñas, O., 333
- Waxler, J., 223
 Wehner, J. M., 143
 Weiner, I., 205
 Weiss, J. F., 573
 Weissman, B. A., 217
 Wellman, P. J., 247
 Wenk, G., 407
 Wessinger, W. D., 323
 Westgate, S. A., 53
 Wetzel, W., 537
 White, N. M., 113
 Willems, J. L., 437
 Willis, R., 569
 Wilson, M. C., 707
 Winter, J. C., 625
 Wirtshafter, D., 45
 Wu, P. H., 355
- Yamamoto, T., 457
 Yoburn, B. C., 525
 Yoshida, H., 187
 Yoshimoto, K., 317
 Young, E. R., 577
 Young, G. A., 373
- Zahnister, N. R., 533
 Zárate-Oleaga, J. A., 15
 Zoloty, S. A., 569